Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Igm Biosciences Inc (NQ: IGMS )

9.300 -0.860 (-8.46%)
Streaming Delayed Price Updated: 3:54 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Igm Biosciences Inc

< Previous 1 2 Next >
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects – 
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations 
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at Three Upcoming Investor Conferences
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
From IGM Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.